Skip to main content
SpringerLink
Log in

Kidney failure after treatment with 90Y-DOTATOC

  • Letters to the editor
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Cybulla M, Steiner SM, Otte A. End-stage renal disease after treatment with 90Y-DOTATOC. Eur J Nucl Med 2001; 28: 1552–1554.

    Article  CAS  PubMed  Google Scholar 

  2. Boerman OC, Oyen WJG, Corstens FHM. Between the Scylla and Charybdis of peptide radionuclide therapy: hitting the tumor and saving the kidney. Eur J Nucl Med 2001; 28:1447–1449.

    Article  CAS  PubMed  Google Scholar 

  3. Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, Maecke HR, Muller J. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 1999; 26:1439–1447.

    Article  CAS  PubMed  Google Scholar 

  4. Hammond PJ, Wade AF, Gwilliam ME, Peters AM, Myers MJ, Gilbey SG, Bloom SR, Calam J. Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue. Br J Cancer 1993; 67:1437–1439.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Behr TM, Sharkey RM, Juweid ME, Blumenthal RD, Dunn RM, Griffiths GL, Bair HJ, Wolf FG, Becker WS, Goldenberg DM. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res 1995; 55:3825–3834.

    CAS  PubMed  Google Scholar 

  6. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med 1998; 25:201–212.

    Article  CAS  PubMed  Google Scholar 

  7. Bernard BF, Krenning EP, Breeman WA, Rolleman EJ, Bakker WH, Visser TJ, Macke H, de Jong M. D-Lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. J Nucl Med 1997; 38:1929–1933.

    CAS  PubMed  Google Scholar 

  8. Moll S, Nickeleit V, Mueller-Brand J, Brunner FP, Maecke HR, Mihatsch MJ. A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy. Am J Kidney Dis 2001; 37:847–851.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Nuclear Medicine and Radiological Chemistry Unit, University Hospitals, Petersgraben 4, 4031, Basel, Switzerland

    Tilmann Schumacher, Christian Waldherr, Jan Mueller-Brand & Helmut Maecke

Authors
  1. Tilmann Schumacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christian Waldherr
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jan Mueller-Brand
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Helmut Maecke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tilmann Schumacher.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schumacher, T., Waldherr, C., Mueller-Brand, J. et al. Kidney failure after treatment with 90Y-DOTATOC. Eur J Nucl Med 29, 435 (2002). https://doi.org/10.1007/s00259-001-0720-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-001-0720-2

Keywords

Search

Navigation